SV2A and Alzheimer disease: More recent immunoblotting studies have revealed reductions in [3H]UCB-J binding but no significant changes in SV2A protein levels in homogenates or synaptosome fractions from the frontal cortex, temporal cortex, or hippocampus of AD patients [72].